Senior Associate Counsel (Corporate Strategy Team)

About the role

Oversee contracting, regulatory document creation and submission across various regulatory regimes
Work closely with regulatory, strategy, and finance teams to ensure seamless execution of company strategy initiatives across all verticals
Contribute and participate in company strategy discussions
Participate in investor relations and fundraising activities
Contribute to drafting and crafting investor presentation and communications materials

Responsibilities

• Oversee contracting, regulatory document creation and submission across various regulatory regimes
• Work closely with regulatory, strategy, and finance teams to ensure seamless execution of company strategy initiatives across all verticals
• Contribute and participate in company strategy discussions
• Participate in investor relations and fundraising activities
• Contribute to drafting and crafting investor presentation and communications materials

Requirements

• 1-3 years of work experience with a premier law firm focused on executing equity capital markets, debt capital markets, and or mergers & acquisitions transactions
• JD or equivalent (US LLM +Bar if foreign law degree)

Qualifications

• Detail-oriented, motivated and focused
• JD or equivalent (US LLM +Bar if foreign law degree)

Skills

• Transaction experience (equity, debt capital markets and/or mergers & acquisitions)

Benefits

• Flexible work schedule

Pay

• Competitive salary based on experience and qualifications

Schedule

• Hybrid work arrangement

Company Overview

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.